Publications & Talks
Our Research / Publications & Talks
Urinary p75 neurotrophin receptor extracellular domain: A biomarker relevant to ALS therapy development.
Rogers ML (presenter), Shepheard S, Wuu J, Andersen P, Schultz D, Benatar M. Urinary p75 neurotrophin receptor extracellular domain: A biomarker relevant to ALS therapy development. Platform presentation at the International Symposium on ALS/MND, Boston, MA, Dec 8-10, 2017.
Randomized, phase II trial of arimoclomol in rapidly progressive SOD1 ALS.
Benatar M (presenter), Wuu J, Atassi N, Cudkowicz M, Schoenfeld D. Randomized, phase II trial of arimoclomol in rapidly progressive SOD1 ALS. Late-breaking session platform presentation at the 27th International Symposium on ALS/MND, Dublin, Ireland, Dec 7-9, 2016.
Quantitative Motor Testing: Biomarker of Pre-Symptomatic ALS?
Benatar M (presenter), Reilmann R, Schubert R, Reyes E, Seleski C, Cooley A, Wuu J. Quantitative Motor Testing: Biomarker of Pre-Symptomatic ALS? Platform presentation at the 27th International Symposium on ALS/MND, Dublin, Ireland, Dec 7-9, 2016.
Pre-Symptomatic ALS genetic counseling and testing: Experience and recommendations.
Benatar M (presenter), Stanislaw C, Reye E, Hussain S, Andersen PM, Wuu J. Pre-Symptomatic ALS genetic counseling and testing: Experience and recommendations. Platform presentation at the 26th International Symposium on ALS/MND, Orlando, FL, Dec 11-13, 2015.
The challenge of early therapeutic intervention in ALS.
Benatar M (invited speaker). The challenge of early therapeutic intervention in ALS. Invited presentation at the 25th International ALS/MND Meeting. Brussels, Belgium, December 2014.
Motor neuron involvement in multi-system proteinopathy: Implications for ALS/MND.
Benatar M (presenter), Fernandez C, Weihl C, Wuu J, Katzen H, Oskarsson B, Steele J, Taylor JP. Motor neuron involvement in multi-system proteinopathy: Implications for ALS/MND. Platform presentation at the 23rd International Symposium on ALS/MND, Chicago, IL, Dec 5-7, 2012.
MRI evidence of disease in pre-symptomatic SOD1+ individuals at risk for developing familial ALS.
Nair G, Wuu J, Gronka S, Walker M, Carew J, Benatar M (presenter). MRI evidence of disease in pre-symptomatic SOD1+ individuals at risk for developing familial ALS. Platform presentation at the 22nd International Symposium on ALS/MND, Sydney, Australia, Nov 30 - Dec 2, 2011.
Telemedicine to facilitate ALS research.
Gronka S, Walker M, Wuu J, Stanislaw C, Fanos J, Atassi N, Jaffa M, Andersen P, Cudkowicz M, Benatar M (presenter). Telemedicine to facilitate ALS research. Platform presentation at the 21st International Symposium on ALS/MND, Orlando, FL, Dec 11-13, 2010.
Tackling the challenges of ALS from a familial perspective.
Gronka S, Wuu J, Usher S, Polak M, Benatar M (presenter). Tackling the challenges of ALS from a familial perspective. Platform presentation at the 20th International Symposium on ALS/MND, Berlin, Germany, Dec 4-10, 2009.
The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers.
Benatar M (speaker). The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers. NEALS Annual Meeting, Nov 1-3, 2022.
The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers.
Benatar M (speaker). The ATLAS Study: Rationale and design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers. ALS One 5th Annual ALS Research Symposium. Virtual, Oct 6-7, 2022.
Evolving Paradigms in ALS Therapy Development.
Benatar M (invited speaker). Evolving Paradigms in ALS Therapy Development. 147th Annual Meeting of the American Neurological Association. Chicago, IL, Oct 22-25, 2022.
Rethinking ALS: Prodrome, Biomarkers, Disease Prevention.
Benatar M (keynote speaker). Rethinking ALS: Prodrome, Biomarkers, Disease Prevention. The 1st Ontario Clinical ALS Day (OCAD). Toronto, Canada, Oct 21, 2022.
Progress Towards ALS Prevention.
Benatar M (keynote speaker). Progress Towards ALS Prevention. The ALS Association 2022 Virtual Advocacy Conference, June, 2022.
Rethinking ALS: Prodrome, Biomarkers, Disease Prevention.
Benatar M (keynote speaker). Rethinking ALS: Prodrome, Biomarkers, Disease Prevention. Expert-in-the-Field speaker at the 10th Annual University of California Irvine Health Neuromuscular Colloquium. Irvine, CA, June, 2022.